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ABSTRACT
Objective: Pharmacoeconomic analyses typically project the expected
cost-effectiveness of a new product for a speciﬁc indication. This analysis
develops a dynamic life-cycle model to conduct a multiindication evalua-
tion using the case of trastuzumab licensed in the United States for both
early-stage and metastatic (or late-stage) human epidermal growth factor
receptor 2 (HER2)-positive breast cancer therapy (early breast cancer
[EBC]; metastatic breast cancer [MBC]), approved in 2006 and 1998,
respectively.
Methods: This dynamic model combined information on expected incre-
mental cost-utility ratios for speciﬁc indications with an epidemiologically
based projection of utilization by indication over the product life
cycle—from 1998 to 2016. Net economic value was estimated as the
cumulative quality-adjusted life years (QALYs) gained over the life cycle
multiplied by a societal valuation of health gains ($/QALY) minus cumu-
lative net direct treatment costs. Sensitivity analyses were performed under
a range of assumptions.
Results: We projected that the annual number of EBC patients receiving
trastuzumab will be more than three times that of MBC by 2016, in part
because adjuvant treatment reduces the future incidence of MBC. Over
this life cycle, the estimated overall incremental cost-effectiveness ratio
(ICER) was $35,590/QALY with a total of 432,547 discounted QALYs
gained. Under sensitivity analyses, the overall ICER varied from $21,000
to $53,000/QALY, and the projected net economic value resulting from
trastuzumab treatment ranged from $6.2 billion to $49.5 billion.
Conclusions: Average ICERs for multiindication compounds can increase
or decrease over the product life cycle. In this example, the projected
overall life-cycle ICER for trastuzumab was less than one half of that in
the initial indication. This dynamic perspective—versus the usual static
one—highlights the interdependence of drug development decisions and
investment incentives, raising important reimbursement policy issues.
Keywords: cost-utility analysis, economics, modeling, pharmaceutical
pricing, product life cycle.
Introduction
Most economic evaluations involving cost-effectiveness analyses
of new pharmaceutical products are performed shortly following
product launch for a speciﬁc indication covered in the license.
They are based on mathematical models that project clinical and
economic outcomes from results of phase III randomized clinical
trials for a typical patient for the expected horizon of clinical
impact. Indeed, such models are often a key element in dossiers
submitted to public and private payers for purposes of coverage
and reimbursement.
In the past decade, we have witnessed the licensing of many
new, innovative advances in biologic agents that work in multiple
cancer types and indications. When these products are launched
for the initial indication, manufacturers will set the price by which
cost-effectiveness is judged. From a payer’s perspective, this evalu-
ation is logical and useful as they see each indication as a separate
“purchase” on behalf of their beneﬁciaries. However, this process
has some limitations and implications from a broader societal and
global perspective that are underappreciated. First, the aggregate
economic value delivered by a new medicine will ultimately be
determined by the different types and number of patients using it
over its life cycle, and this may include totally new indications
(often at different doses). Second, not only does the cost-
effectiveness of a product vary among individual patients, but
also the economic value will typically vary systematically across
indications. Because the price per milligram of a pill often cannot
be varied across indications, the actual cost-effectiveness achieved
will generally vary. This creates a dilemma for manufacturers
working within a reimbursement environment that simulta-
neously ﬁxes the price at launch for the duration of the product life
cycle and evaluates the product by applying a cost-effectiveness
threshold: should potential future indications have some impact
on the proposed initial product price?
In oncology, for example, both for reasons of safety and for
risk–beneﬁt, it is common to ﬁrst conduct clinical trials in the
most severely ill patients (e.g., patients with metastatic disease
who have failed ﬁrst- or second-line therapies). If efﬁcacy is
demonstrated at reasonable tolerability in this situation, then the
therapy can be tested at earlier stages of disease progression, for
example, moving from later stage, metastatic use to treatment at
early diagnosis, called “adjuvant” use (e.g., in combination with
surgery). This process of drug development and testing usually
takes 8–12 years for the initial indication, and several more years
for each subsequent indication [1]. Once a therapy is approved in
an early-stage, adjuvant setting, the characteristics of the patients
who progress to metastatic disease and those individuals who are
newly diagnosed with metastases may be quite different from
patients originally diagnosed with metastatic disease at the begin-
ning of the product life cycle or during the registration clinical
trials. Early therapy will affect the later incidence of metastatic
disease as well as the treatment of adjuvant patients. Moreover,
before a product is approved for use in the adjuvant setting, there
can also be changes in the standard of care in the metastatic
setting.
This analysis takes a broader long-term perspective, asking
what is the overall cost-effectiveness across multiple indications
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throughout the product life cycle and what is the aggregate
economic value delivered. The objective was to develop a
dynamic life-cycle modeling (DLM) approach, and to apply it to
a case example. We evaluated a targeted cancer therapy, trastu-
zumab (Herceptin®, Genentech, Inc., South San Francisco, CA),
a monoclonal antibody approved for treatment of human epider-
mal growth factor receptor 2 (HER2)-positive breast cancer in
combination with chemotherapy. This analysis considers both
the treatment for metastatic HER2-positive breast cancer
(approved by the Food and Drug Administration in 1998) and
the more recently approved (2006) indication for adjuvant treat-
ment of early-stage HER2-positive breast cancer. We chose this
example because trastuzumab has a more recently approved
second indication, national-level epidemiological data were
available, and data from suitable indication-speciﬁc cost-
effectiveness analyses were available.
Study Data and Methods
Background and Model Overview
A DLM approach combines information on expected incremental
cost-effectiveness ratios (ICERs) with an epidemiologically based
projection of utilization by indication over the product life cycle.
The effective product life cycle for biologics is not ﬁxed given the
current lack of a regulatory pathway in the United States for
so-called “biosimilars” or “follow-on biologics” and the potential
entrance of competing branded biologics in the same class. For
purposes of this exercise, the “end” of the product life cycle is
assumed to be 10 years after the launch in adjuvant treatment (i.e.,
through 2016). This DLM projection thus has three major com-
ponents: a forecast of the volume of trastuzumab use over the
product life cycle—from initial launch in 1998 to 2016, an
estimate of the average cost-effectiveness (i.e., the average ICER)
in metastatic treatment over this period, and an estimate of the
average ICER in adjuvant treatment following approval in this
indication eight years after the initial launch.
Projecting Disease Incidence
Approximately 20% to 25% of patients with breast cancer will
have HER2-positive disease, which is associated with a poor
prognosis [2,3]. Trastuzumab is a monoclonal antibody that
targets HER2, and is approved for the treatment of HER2-
positive metastatic breast cancer either as ﬁrst-line therapy in
combination with paclitaxel or as second- or third-line mono-
therapy. For this analysis, we relied on previously published and
publicly available data to project the economic impact of
trastuzumab.
To our knowledge, there are no published projections of the
volume of long-term trastuzumab use in the United States. The
approach we used projects an increasing volume of the use of
trastuzumab from 1998 to 2016 based on estimates of the antici-
pated annual incidence of metastatic breast cancer and early-
stage breast cancer in the United States. These estimates were
derived from Surveillance Epidemiology and End Results (SEER)
data from the National Cancer Institute, and assumed that 25%
of patients tested are HER2-positive [4]. In the years prior to
approval of the adjuvant indication, the volume of utilization
was based solely on metastatic breast cancer patients. After
approval of the adjuvant indication in November 2006, the
volume of use was projected to shift to include women receiving
adjuvant therapy for EBC as well as women receiving ﬁrst-line
metastatic treatment, whether initially diagnosed, or for recur-
rent disease. Furthermore, given that data from the joint analysis
of the National Surgical Adjuvant Breast and Bowel Project B-31
and the North Central Cancer Treatment Group N9831 trials
demonstrated that the addition of trastuzumab to a standard
adjuvant regimen reduced the risk of recurrence by 52%
(P < 0.001) and improved survival by 33%, there is an antici-
pated reduction in the number of future metastatic breast cancer
patients [5].
Projecting Volume of Trastuzumab Use
The projection of the volume of use over the product life cycle
was based on demographic projections, epidemiological esti-
mates, and assumptions about use rates among candidate (i.e.,
HER2-positive) patients. The female population was divided into
ﬁve age groups: less than 21, 21–39, 40–54, 55–64, and more
than 64. Data on US census age-speciﬁc subpopulations through
2016 were aggregated to within these age groups [6]. An analysis
of the SEER registry for the period 1999–2001 provided the
incidence rates of breast cancer used in the analysis: these are
shown in Table 1 for both EBC and newly diagnosed MBC
patients. An assumption was made that 25% of the previously
diagnosed early patients in SEER would later suffer a recurrence.
An analysis of recent SEER data was used to estimate the share
of EBC patients who are node-negative low-risk, node-negative
high-risk, and node positive. Based on these shares, the use rate
in the base case for HER2-positive patients was assumed to be
60% for all patients in the metastatic setting and 70% for node-
positive and high-risk node-negative patients in the adjuvant
setting. This also reﬂects the impact of a number of factors,
including that not all women will be tested, some will have
Table 1 Input parameters for volume of use projection
Input parameters Base-case Range Source
Incidence rates (per 100,000
women) for early breast
cancer* by age:
SEER 1999–2001
<21 years 0.02 —
21–39 years 23.2 —
40–54 years 161.5
55–64 years 317.1 —
65+ years 372.0 —
Incidence rates (per 100,000
women) for newly
diagnosed metastatic
disease*:
SEER 1999–2001
<21 years 0 —
21–39 years 1.1 —
40–54 years 6.6
55–64 years 15.1 —
65+ years 19.4 —
Incidence of metastatic disease
among women diagnosed
previously
25% Assumption
Incidence of HER2-positive
breast cancer among
women diagnosed with
breast cancer
25% Slamon et al. [2]
Early breast cancer
distribution at diagnosis:
SEER
Node-negative, low-risk 17%
Node-negative, high-risk 50%
Node positive 33%
Trastuzumab utilization
rate (%) by status:
Assumptions
Node-negative, low-risk 0% —
Node-negative, high-risk 70% 50% to 90%
Node positive 70% 50% to 90%
Metastatic 60% 50% to 90%
*Both HER2-positive and HER2-negative.
SEER, Surveillance Epidemiology and End Results; HER2-positive, human epidermal growth
factor receptor positive.
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comorbidities that limit trastuzumab use, some may not have
adequate insurance coverage, and some will choose not to receive
treatment.
Indication-Speciﬁc Cost-Utility Ratios
Several studies report on the cost-effectiveness of trastuzumab in
either the metastatic [7,8] or adjuvant settings [9–11] using
Markov models to assess the incremental lifetime costs and
QALYs of the addition of trastuzumab in metastatic and early-
stage adjuvant breast cancer. The MBC models were based on the
data from the trials reported in Slamon et al. (2001) [12]. The
EBC models were based on the data from the trials reported in
Romond et al. (2006) [5]. We developed the base case MBC and
EBC cost-effectiveness ratios for trastuzumab based on the
models described above.
The number of QALYs gained and the incremental lifetime
cost per QALY gained were estimated from the studies cited
above that used Markov models, relying in varying degrees of
clinical trial data and published aggregate results. These assump-
tions are summarized in Table 2 for both metatstatic and adju-
vant treatment. The Markov models included costs for: 1) HER2
testing (using immunohistochemistry and/or ﬂuorescence in situ
hybridization); 2) trastuzumab therapy based on average whole-
sale prices for medication costs and Medicare reimbursement
rates for procedures and resources; 3) patients with EBC were
assumed to receive one year of trastuzumab in the adjuvant
setting and were treated with trastuzumab until disease progres-
sion in the metastatic setting; 4) adverse event monitoring; and 5)
treatment of adverse events. In the adjuvant setting, costs for
treating metastatic disease were also included for those patients
projected to progress over time. The indication-speciﬁc outcome
measures for the model were QALYs and were based on reported
projections from literature and clinical efﬁcacy reported in the
studies cited above. Clinical outcomes included survival, prob-
ability of recurrence for EBC, time to progression for MBC, and
adverse events including the incidence of cardiac dysfunction.
The base case estimates for the costs and QALYs for trastu-
zumab in the metastatic and adjuvant indications are presented
in Table 2. There were multiple sources available for the cost-
effectiveness of trastuzumab in the metastatic setting. The
assumed MBC ICER represents a combination of two studies,
using utility weights from Elkin et al. [7] and survival estimates
from Hornberger et al. [8], but also with updated drug cost. As
Hornberger et al. had access to the original trial data and used
propensity scoring to adjust for crossovers following progres-
sion, their survival estimates were used. For the cost-effectiveness
of trastuzumab in the adjuvant setting, all data elements were
based on the work of Garrison et al. [9], whose estimated ICER
falls between two other recently published studies [10,11] and
for which we had access to full model, which is necessary for
these calculations.
Dynamic Life-Cycle Cost-Utility
We examined life-cycle cost-effectiveness using several measures.
The primary measure was an overall life-cycle cost-effectiveness
ratio that was discounted to 1998 based on the projected costs
and QALYs for all patients receiving trastuzumab between 1998
and 2016. This overall, cumulative ICER was computed by mul-
tiplying the mean QALYs gained and mean costs separately by
the estimated number of patients with HER2-positive breast
cancer in the respective adjuvant and metastatic settings in each
year.
QALYS gained and costs were discounted at 3% and were
cumulated separately and then divided to calculate the overall
life-cycle ICER.
Overall Life-Cycle ICER
Discounted MBC_Costs EBC_Costs
=
+( ){ Σ }
+( ){ }Discounted MBC_QALYs EBC_QALYsΣ
Where:
MBC_QALYs = mean discounted MBC_QALY per patient ¥
S (MBC patients over the 19-year period);
EBC_QALYs = mean discounted EBC_QALY per patient ¥
S (EBC patients over the 19-year period);
MBC_Costs = mean discounted MBC_Cost per patient ¥
S (MBC patients over the 19-year period); and
EBC_Costs = mean discounted EBC_Cost per patient ¥
S (EBC patients over the 19-year period)
We also calculated this ﬁgure on a “history to date” basis to
examine how it changes over time. For comparison, we calcu-
lated two alternative “naive” estimates to understand how a
proper accounting over the life cycle would compare. These two
measures were a lifetime weighted average and annual weighted
average, both without discounting to 1998 and based only on the
mean ICERs and volume of use. Proper calculation of the overall
life-cycle ICER requires speciﬁc information on both the numera-
tor and denominators for each of the two indications.
Aggregate Economic Value
We deﬁned net economic value as the potential “social surplus”
as deﬁned in economics as the sum of consumer surplus and
producer surplus. Essentially, it is the amount by which aggregate
societal willingness to pay for beneﬁts exceed the costs of pro-
viding them. This requires an assumption about the willingness
to pay for a QALY gained. As there is no consensus about a
speciﬁc value, we use a range of $50,000–$150,000, reﬂecting
the variation of what analysts have used in practice [13,14]. The
gross life-cycle economic value is deﬁned as the discounted
QALYs gained multiplied by the mean threshold value T that
society places on a QALY:
Gross Economic Value T*ndMBC T*ndEBC= +( )
Where T is the threshold value society places on a QALY and is
varied between $50,000/QALY and $150,000/QALY.
ndMBC = discounted S MBC_QALYs over the 19-year period
ndEBC = discounted S EBC_QALYs over the 19-year period
Table 2 Assumptions regarding the cost-effectiveness of trastuzumab in
metastatic and early breast cancer
Inputs*
Costs and outcomes
of treatment for
early breast
cancer†
Costs and outcomes
of treatment for
metastatic breast
cancer‡
Total costs—no trastuzumab $28,749 $40,000
Total costs with trastuzumab $73,672 $87,728
QALY: no trastuzumab 10.08 0.70
QALY: trastuzumab 11.78 1.26
Difference
Cost $44,923 $47,728
QALYS 1.70 0.56
Incremental cost/QALY
gained (ICER)
$26,417 $85,676
*All costs and outcomes discounted at 3% annual rate.
†Garrison et al. [9].
‡Based on current drug costs, survival estimates from Hornberger et al. [8] and utility weights
from Elkin et al. [7].
QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.
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The net economic value was thus deﬁned as the difference
between this gross willingness to pay and the incremental costs of
providing trastuzumab over the entire period, that is, the pro-
jected sales of trastuzumab minus the net of other treatment costs
(discounted at 3%).
Impact of Adjuvant Use on Metastatic Use
Adjuvant use of trastuzumab is expected to reduce the down-
stream use of trastuzumab in the metastatic indication. Projected
ICERs for EBC must include an assumption about whether
future MBC patients will receive trastuzumab. For example,
Garrison et al. [9] assumed this for their base case. This raises
a question of potential double-counting in the epidemiological
projections. In the life-cycle incidence forecasts, we have dis-
tinguished between newly diagnosed MBC and previously diag-
nosed MBC patients. This could lead to an overstatement of both
the costs of trastuzumab and the beneﬁts in terms of QALYs
gained. We attempted to estimate the potential size of this bias by
performing the life-cycle calculation without including the pre-
viously diagnosed patients, assuming they were fully reﬂected in
the CE ratio for adjuvant patients.
Sensitivity Analyses
Our approach to sensitivity analyses was to vary deterministi-
cally four critical drivers: the uptake of trastuzumab in metastatic
and adjuvant use, and the mean ICERs in metastatic and adju-
vant use. The former ranged from 50% to 90%, while the mean
ICER in metastatic use was varied from $70,000 to $115,000,
and was varied from $15,000 to $40,000 in adjuvant use. These
ranges should encompass the bulk of the uncertainty generated
by all of the underlying variables in each of these components.
Results
As shown in Figure 1, by 2016, the number of patients treated
annually with adjuvant trastuzumab was projected to be
approximately three times the number of patients treated with
trastuzumab in the metastatic setting. Over the entire period, an
estimated 319,000 US women with HER2-positive breast cancer
are projected to receive adjuvant trastuzumab and 161,000 are
projected to receive treatment for metastatic breast cancer.
Between 1998 and 2016, the cumulative net cost of trastuzumab
was projected to be $15.4 billion and the cumulative QALYs
gained were projected to be 432,547. The cumulative incremen-
tal cost-utility ratio was $35,590 per QALY gained. Changes in
this cumulative ratio over time are reﬂected in Figure 2. As this is
below most commonly cited thresholds, trastuzumab use appears
to have a net surplus. When these QALYs were valued at varying
rates of societal willingness to pay from $50,000 to $150,000,
the projected gross economic value of trastuzumab treatment due
to QALY gains ranged from $21.6 billion to $64.9 billion. Sub-
tracting the cumulative net cost of trastuzumab, the economic
value to society is projected to be between $6.2 billion to $49.5
billion Or viewed alternatively, the proportional reward to the
manufacturer represents as much as 71% of the social surplus
generated to as little as about 24%, depending on the societal
willingness to pay for QALYs.
The overall ICER results compared to the indication-speciﬁc
estimates are depicted in Figure 3. Given the change in volumes
of use for the two indications, this estimate is lower than either
naïve estimate—a mean annual ICER for 2016 of $40,652 per
QALY or a mean cumulative (nondiscounted) ICER of $46,262
per QALY.
In the sensitivity analyses, as shown in Table 3, the overall
life-cycle ICER varied from $32,914 to $42,129 as the utilization
rate varied, and the overall life-cycle ICER varied from $21,210
to $52,842 as the indication-speciﬁc ICERs were varied.
Excluding metastatic patients who were previously diagnosed
to adjust for potential double-counting reduces the overall life-
cycle ICER by 18% to $29,357, and reduces total QALYs gained
by 10% to 384,675. This also decreases the gross life-cycle
economic value from $21.6 billion to $19.2 billion at the low
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end, and from $64.9 billion to $57.7 billion at the high end.
However, this probably overstates the reduction somewhat as
Garrison et al. [9] conservatively assume that all patients who
initially received adjuvant trastuzumab—as well as those who
did not—receive trastuzumab after metastatic progression.
Discussion
We developed a DLM approach and applied the methodology to
the breast cancer drug trastuzumab. Speciﬁcally, we found that
the cumulative, life-cycle ICER trastuzumab was $35,590, with a
range of $21,000–$53,000 in sensitivity analyses. The gross life-
cycle value was estimated to be between $21.6 billion and $64.9
billion, with a corresponding net economic value of $6.2 billion–
$49.5 billion. The overall life-cycle ICER for trastuzumab is less
than one half of the projected ICER in the initial indication, and
the aggregate economic value is much greater as result of the
second adjuvant indication. These results suggest that indication-
speciﬁc models may have signiﬁcant limitations for informing
policy decisions for drugs with multiple indications licensed over
time.
Applying a DLM approach to consider an innovative thera-
peutic agent highlights the importance of perspective. A short-
term perspective focusing on indication-speciﬁc cost-effectiveness
offers a different view than a longer-term perspective that recog-
nizes the interdependence of drug development decisions and
investment incentives. US private payers are generally expected
to take a short-term perspective, considering value for money
spent on an indication-by-indication basis. Reimbursement
systems, particularly in Europe, do not adjust prices or reim-
bursement rates in response to new information on cost-
effectiveness with new indications. In the United States,
manufacturers can and do often increase the prices of branded
products greater than the rate of general inﬂation. The net eco-
nomic surplus would be lower in real terms if the real price of
trastuzumab increases over this period. In any case, establishing
evidence- and value-based reimbursement systems in this situa-
tion, particularly with ﬁxed prices across indications at any point
in time, is difﬁcult.
Reimbursement systems that do not account for changing
value across indications or over time may produce suboptimal,
long-term societal outcomes. Under the patent system, drug
prices for branded products can also be seen as a reward for
innovation, with potentially far-reaching implications for incen-
tives to undertake future innovative research and development.
For example, the calculations of Philipson and Jena [15] for
HIV drugs suggest that manufacturers are receiving only about
5% of the social surplus they create. They argue that this low
proportion provides a much smaller incentive for innovation. In
this trastuzumab case, the estimated range of surplus reward to
the manufacturer varied between 24% and 71%, depending on
the threshold value for a QALY. A role for the dynamic, long-
term perspective is exempliﬁed in oncology where early clinical
trials are focused on the sickest patients, followed only many
years later in patients diagnosed earlier where the potential
beneﬁt is greater. This has signiﬁcant implications for reim-
bursement systems, the value of information generated by addi-
tional research, and incentives for investment. The recent debate
between Claxton and Towse [16,17] about the “value-based”
pricing proposal of the UK Ofﬁce of Fair Trading report [18]
has raised the possibility of ex post payments based on perfor-
mance, including potentially different payments for different
indications. The potential positive effects on incentives for
investment have been noted by Thornton [19]. Lundin and
Ramsberg [20] have recently argued theoretically that a
Figure 3 Indication-speciﬁc and overall life-cycle
incremental cost-effectiveness ratios (ICERs).
Table 3 Sensitivity of life-cycle ICER to use rates (as a percentage of
incident population) and to variations in indication-speciﬁc ICERs (base
case in italics)
Sensitivity to use rates as percentage of incident population
MBC
EBC 50% 60% 70% 90%
90% $32,914 $33,849 $34,751 $36,465
70% $34,471 $35,590 $36,662 $38,674
60% $35,567 $36,808 $37,989 $40,188
50% $37,008 $38,398 $39,710 $42,129
Sensitivity to variations in indication-speciﬁc ICERs
MBC ICER
EBC ICER $70,000 $85,676 $115,000
$15,000 $21,210 $21,658 $22,191
$26,417 $34,398 $35,590 $37,053
$40,000 $47,602 $49,917 $52,842
Source: Authors’ calculations.
ICER, incremental cost-effectiveness ratio; MBC, metastatic breast cancer; EBC, early breast
cancer.
1122 Garrison and Veenstra
“dynamic cost-effectiveness rule” could improve incentives for
research and development.
There are several limitations to our analysis. First, these cal-
culations are based on projections and may not represent actual
practice in terms of either cost-effectiveness achieved or future
volumes of use. The model is only from a US perspective, although
a more global view would be appropriate for considering returns
to R&D. The model also does not estimate any impact on volume
of trastuzumab use or a revaluation of consumer surplus if there
are follow-on competitive compounds (including the entry of
branded competitors). If such a competition were to lower use,
then the aggregate surplus generated by trastuzumab would be
lower, although if price competition lowered prices, then the share
of surplus going to the manufacturer would be reduced. And the
model does not include any consideration of the use of trastu-
zumab in other indications, including “off-label” indications such
as third- or fourth-line metastatic treatment, where formal testing
has not been conducted. An oncology drug could be less cost-
effective in such indications, which would raise its overall life-
cycle cost-effectiveness ratio, although potentially still increasing
aggregate net economic value.
Also, the time horizon to 2016 was chosen to represent a
plausible period of limited competition from follow-ons which
would also require years of testing to establish efﬁcacy in both of
these indications. A slightly shorter effective patent protection
would reduce the gross economic value generated, but would
have limited impact on the life-cycle ICER or the share of surplus
reward, which varies more with the threshold value for a QALY.
In addition, our estimates took a payer perspective, which did
not include any indirect cost savings or time costs. Presumably,
improved cancer survival improves the labor force participation
and contributions of these patients, increasing the overall social
surplus. This analysis was conducted in real terms (2006 US
dollars) discounted to 1998. As is customary, “inﬂation” in either
drug or other medical prices is not included in the projections.
Also, we did not consider the impact of any fall in the real price
of trastuzumab if there were any competition from a biosimilar
product during this period, or of any real increase in price
because, as discussed above, manufacturers in the United States
often increase prices of branded products over time. Further-
more, we did not model the impact of the potential competitor
lapatinib, an oral chemotherapeutic agent recently approved for
HER2-positive patients whose metastatic disease has progressed
after receiving regimens including trastuzumab.
Our calculations to consider the impact of double-counting
suggest that our projection of the life-cycle ICER could be too
conservative (i.e., biased upward) since we assume that all recur-
rent MBC patients receive trastuzumab. Note that although we
project that 84% of metastatic use in 2016 would be for previ-
ously diagnosed patients, the vast majority of overall use by then
would be for EBC patients receiving adjuvant therapy. Nonethe-
less, this could be an important area for future research, as it
would be useful to have a reliable estimate of the impact of
improved adjuvant outcomes on metastatic incidence and costs.
Conclusions
Indication-speciﬁc cost-utility or cost-effectiveness models do not
account for the important interdependence of drug development
and expanded indications over time: the development and
approval of subsequent indications is contingent upon success in
those developed ﬁrst. Average ICERs for multi-indication com-
pounds can increase or decrease over the product life cycle. This is
especially true in oncology where initial research on safety and
efﬁcacy occurs in the most critically ill patients: only after efﬁcacy
is demonstrated in this situation can new therapies be tested at
earlier stages of disease. The ﬁeld of pharmacoeconomics and
reimbursement policies should give greater attention to dynamic,
long-term aspects of drug pricing and reimbursement policies and
how they affect incentives for innovation and drug development.
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